Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Immune-Onc Therapeutics, founded in 2016 and headquartered in Palo Alto, California, is a clinical-stage company specializing in the development of novel myeloid checkpoint inhibitors for cancer treatment. The company focuses on creating innovative immunotherapies that harness the body's immune system to combat blood cancers and solid tumors. With a strong presence in the healthcare and biotechnology industry, Immune-Onc Therapeutics has raised a total of $106.32 million in funding to date.
As a privately held company, Immune-Onc Therapeutics has not yet announced any plans for an initial public offering (IPO). The company's progress in developing cutting-edge cancer treatments could potentially attract investor interest, but it's important to note that there are currently no official reports or rumors regarding an IPO for Immune-Onc Therapeutics.
Factors that may influence the company's decision to go public in the future could include its clinical trial progress, market conditions in the biotechnology sector, and the need for additional capital to fund research and development. However, as with any private company, the decision to pursue an IPO remains speculative and would depend on various internal and external factors.
For investors interested in the biotechnology sector, it's advisable to keep an eye on Immune-Onc Therapeutics' developments and any official announcements regarding its future plans. As always, potential investors should conduct thorough research and consider consulting with financial advisors before making investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Immune-Onc Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative immunotherapy space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech and healthcare sectors, including companies developing cutting-edge cancer treatments, with lower minimum investments than traditional private equity opportunities.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
